Skip to Content
Print Save

Aprepitant Disease Interactions

There is 1 disease interaction with aprepitant:

Moderate

Aprepitant (applies to aprepitant) liver disease

Moderate Potential Hazard, Moderate plausibility.

Aprepitant is primarily metabolized by the liver. In studies of patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9), aprepitant was well tolerated and no clinically significant alterations in its pharmacokinetics were observed. Thus, no dosage adjustment of aprepitant is necessary in this patient population. However, there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score > 9), and caution is advised if aprepitant is used in such patients.

References

  1. "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.

Aprepitant drug interactions

There are 390 drug interactions with aprepitant

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer